Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;24 Suppl 4(0 4):S15-26.
doi: 10.1097/01.aids.0000390704.35642.47.

Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?

Richard Hayes  1 , Deborah Watson-Jones, Connie Celum, Janneke van de Wijgert, Judith Wasserheit
Affiliations

Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?

Richard Hayes et al. AIDS. 2010 Oct.

Abstract

Observational and biological data provide compelling evidence of the importance of sexually transmitted infections (STIs) in HIV transmission, but only one of nine intervention trials has shown an effect. This article reviews the observational studies, critically examines the nine randomized controlled trials evaluating the impact of STI treatment interventions on HIV incidence, and discusses implications for HIV prevention policy, programs and future research. The role of other vaginal infections is also briefly considered. In aggregate, the evidence strongly supports the concept that STI treatment prevents HIV infection. However, issues in trial design and conduct, including HIV epidemic phase, STI prevalence, intervention in comparison groups, and power have affected five of the six trials of treatment of curable STIs. In the three herpes intervention trials, antivirals for HSV suppression were insufficiently potent to alleviate persistent genital inflammation in HIV-negative HSV2-positive persons, and the reduction in HIV levels in HIV-positive persons was insufficient to reduce HIV transmission. It is time for a new phase of exploration of how, when, and in whom to include STI control as a key component of HIV prevention, driven by basic research to elucidate the mechanisms by which STIs and vaginal infections facilitate HIV transmission. From a policy perspective, treatment of curable STIs is an essential part of primary healthcare and is a cheap, simple, and effective intervention when appropriately targeted and delivered. It should be promoted as an essential component of HIV control programs in communities in which the burden of STIs is substantial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of results of nine randomised trials of STI treatment for HIV prevention. Studies are grouped as (i) community-randomised trials of population-level curable STI treatment interventions; (ii) individually-randomised trials of curable STI management in HIV-negative sex workers; (iii) individually-randomised trials of herpes suppressive therapy in HIV-negative or HIV-positive subjects. RR shows relative risk of HIV incidence in intervention arm compared with control arm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abad CL, Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. Journal of Chemotherapy. 2009;21:243–252. - PubMed
    1. Austin MN, Beigi RH, Meyn LA, Hillier SL. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. Journal of Clinical Microbiology. 2005;43:4492–4497. - PMC - PubMed
    1. Auvert B, Lissouba P, Cutler E, Zarca K, Puren A, Taljaard D. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. Journal of Acquired Immunedeficiency Syndrome. 2010;53:111–116. - PMC - PubMed
    1. Barnabas R, Weiss HA, Wasserheit JN. Role of co-infections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis of malaria, HSV-2 and TB co-infections; ISSTDR Conference; London. 2009; Abstract OS3.3.03. - PMC - PubMed
    1. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. Journal of Infectious Diseases. 2008;198:1804–1808. - PMC - PubMed

Publication types